ArticleOncotarget2015
miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- A Comprehensive Guide on Epigenetics' Precision Role in Uncommon "Rare" Cancers' Biology and Treatment Frontiers.Sub-cellular biochemistry · 2026Review
- MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies.Cancer cell international · 2025Review
- Nuclear miRNAs as transcriptional regulators in processes related to various cancers (Review).International journal of oncology · 2024Review
- Non-Canonical Targets of MicroRNAs: Role in Transcriptional Regulation, Disease Pathogenesis and Potential for Therapeutic Targets.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism.iScience · 2023Article
- The SMAD2/miR-4256/HDAC5/p16Oncology research · 2023Article
- The role of ncRNAs in neuroblastoma: mechanisms, biomarkers and therapeutic targets.Biomarker research · 2022Review
- Vitronectin-based hydrogels recapitulate neuroblastoma growth conditions.Frontiers in cell and developmental biology · 2022Article
- Non-Coding RNAs Participate in the Pathogenesis of Neuroblastoma.Frontiers in oncology · 2021Review
- Review
- miR‑337‑3p inhibits gastric tumor metastasis by targeting ARHGAP10.Molecular medicine reports · 2020Article
- Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration.British journal of cancer · 2020Article
- Updating the role of matrix metalloproteinases in mineralized tissue and related diseases.Journal of applied oral science : revista FOB · 2019Review
- miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.Cell cycle (Georgetown, Tex.) · 2019Article
- Article
- Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells.Cancer biomarkers : section A of Disease markers · 2019Article
- MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.Seminars in cancer biology · 2018Review
- Article
- Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer.Molecular cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Recent evidence shows the emerging roles of endogenous microRNAs (miRNAs) in repressing gene transcription. However, the miRNAs inhibiting the transcription of matrix metalloproteinase 14 (MMP-14), a membrane-anchored MMP crucial for the tumorigenesis and aggressiveness, still remain largely unknown. In this study, through mining computational algorithm program and genome-wide Argonaute profiling dataset, we identified one binding site of miRNA-337-3p (miR-337-3p) within the MMP-14 promoter. We demonstrated that miR-337-3p was under-expressed and inversely correlated with MMP-14 expression in clinical specimens and cell lines of neuroblastoma (NB), the most common extracranial solid tumor in childhood. Patients with high miR-337-3p expression had greater survival probability. miR-337-3p suppressed the promoter activity, nascent transcription, and expression of MMP-14, resulting in decreased levels of vascular endothelial growth factor, in cultured NB cell lines. Mechanistically, miR-337-3p recognized its binding site and recruited Argonaute 2 to facilitate the enrichment of repressive epigenetic markers and decrease the binding of RNA polymerase II and specificity protein 1 on the MMP-14 promoter. Gain- and loss-of-function studies demonstrated that miR-337-3p suppressed the growth, invasion, metastasis, and angiogenesis of NB cells in vitro and in vivo. In addition, restoration of MMP-14 expression rescued the NB cells from changes in these biological features. Taken together, these data indicate that miR-337-3p directly binds the MMP-14 promoter to repress its transcription, thus suppressing the progression of NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.